文献速递湿疹皮炎与荨麻疹

度普利尤单抗相关眼部不良事件的发生率与危险因素:真实世界前瞻性研究

Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-07-27

该前瞻性单中心真实世界研究纳入46例接受度普利尤单抗治疗的成人特应性皮炎患者,治疗前后由眼科医生系统检查。34.8%患者出现眼部不良事件,多为轻中度,2例因眼部不良事件停药;多数为干眼症或浅层点状角膜炎。既往干眼伴浅层点状角膜炎、眼睑湿疹、食物过敏史及IgE>1000 kU/L与眼部不良事件相关。

要点

  • 度普利尤单抗治疗成人特应性皮炎患者中34.8%出现眼部不良事件,多为轻中度。
  • 既往干眼伴浅层点状角膜炎、眼睑湿疹、食物过敏史及IgE>1000 kU/L可能为危险因素。
  • 有眼睑湿疹或干眼症状者可在启动度普利尤单抗前转诊眼科并考虑预防性眼部保湿。

核心结论

  • 度普利尤单抗治疗成人特应性皮炎患者中眼部不良事件发生率为34.8%,多数为轻中度,2例因眼部不良事件停药。
  • 既往干眼伴浅层点状角膜炎、眼睑湿疹、食物过敏史及血清IgE>1000 kU/L与度普利尤单抗相关眼部不良事件相关。

研究设计与样本

  • 前瞻性、单中心、真实世界研究,纳入46例接受度普利尤单抗治疗的成人特应性皮炎患者,治疗前及治疗期间由眼科医生系统检查。
  • 患者中位年龄41.1岁,中位基线SCORing Atopic Dermatitis评分为46.0(IQR:34.5-55.5)。

主要发现

  • 34.8%的患者发生眼部不良事件,大多为轻中度,2例因眼部不良事件需停药。
  • 多数患者出现干眼症或原有干眼症加重,伴浅层点状角膜炎(SPK);6例发生结膜炎。
  • 既往干眼伴SPK的比值比(OR)为6.3(95%CI:1.3-31.6)。
  • 既往眼睑湿疹的OR为8.7(95%CI:1.8-40.6)。
  • 食物过敏史的OR为3.8(95%CI:1.002-14,070),血清IgE>1000 kU/L的OR为10.6(95%CI:1.2-91.3)。

关键数值与推荐

  • 眼部不良事件定义为治疗前及治疗期间眼科检查发现的眼部异常。
  • 危险因素包括既往干眼伴SPK(OR 6.3,95%CI 1.3-31.6)、眼睑湿疹(OR 8.7,95%CI 1.8-40.6)、食物过敏史(OR 3.8,95%CI 1.002-14,070)及IgE>1000 kU/L(OR 10.6,95%CI 1.2-91.3)。

临床怎么用

  • 特应性皮炎患者若存在眼睑湿疹或干眼症状,可在启动度普利尤单抗前转诊眼科,考虑开始预防性眼部保湿措施。
  • 治疗期间应关注干眼症及浅层点状角膜炎等眼部不良事件,必要时请眼科评估。

局限性

  • 单中心、真实世界研究,样本量46例,结果需多中心及转化研究进一步验证。
  • 食物过敏史OR的95%CI上限达14,070,提示估计不精确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dupilumab is approved for use in moderate-to-severe atopic dermatitis (AD) and as an add-on maintenance treatment in patients suffering from severe asthma with type 2 inflammation. Ocular adverse events (OAEs) have been reported with dupilumab almost exclusively in patients treated for AD. OBJECTIVES: The objectives of this study were to describe the incidence and nature of dupilumab-induced OAEs and to assess the potential predisposing factors. PATIENTS AND METHODS: We conducted a prospective, single-centre, real-life study in adult AD patients treated with dupilumab, who were systematically examined by an ophthalmologist before and during treatment. RESULTS: Forty-six patients were included prospectively with a median age of 41.1 years and a median initial SCOring Atopic Dermatitis of 46.0 (IQR: 34.5-55.5). OAEs concerned 34.8% of patients and were mostly of mild to moderate severity. Two patients had to discontinue treatment due to OAE. The majority of patients developed or aggravated dry eye disease, with superficial punctate keratitis (SPK). Six patients developed conjunctivitis. Dupilumab-induced OAEs were associated with the following pre-existing parameters: dry eye disease with SPK (Odds ratio (OR); 6.3 [95% confidence interval (CI): 1.3-31.6]), eyelid eczema (OR: 8.7 [95%CI: 1.8-40.6]), history of food allergy (OR 3.8 (95% CI: 1.002-14,070) and IgE serum level> 1000 kU/L (OR:10.6 [CI 95%: 1.2-91.3]). CONCLUSION: Atopic dermatitis patients with eyelid eczema or dry eye disease symptoms may be referred to an ophthalmologist before starting dupilumab to consider initiating preventive eye hydration measures. Further multicentric and translational studies are warranted to better explain OAEs pathophysiology.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Touhouche AT, Cassagne M, Bérard E, et al. Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study. J Eur Acad Dermatol Venereol. 2020. PMID: 32521566. doi:10.1111/jdv.16724

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。